Zhejiang Huahai Pharmaceutical Secures Orphan Drug Designation for HB0034
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received orphan...
Auto-immune
AbbVie’s Rinvoq Demonstrates Sustained Efficacy in Late-Stage Atopic Dermatitis Study
AbbVie (NYSE: ABBV) has announced late-stage results for its JAK inhibitor Rinvoq (upadacitinib) in the...
Janssen Unveils Promising Clinical Data on IL-23 Blockers for Psoriasis
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) is showcasing new clinical data...
Bio-Thera Solutions’ BAT1806 Receives US FDA Approval as Biosimilar to Actemra/RoActemra
Bio-Thera Solutions Ltd (SHA: 688177), a China-based biopharmaceutical company, announced that its biosimilar version of...
Sanofi Enters Collaboration with Teva for IBD Drug TEV’574 Development
Sanofi (NASDAQ: SNY) has entered into a collaboration agreement with Teva (NYSE: TEVA) for the...
Takeda Receives FDA Approval for Subcutaneous Entyvio as UC Maintenance Therapy
The US Food and Drug Administration (FDA) has granted Japan’s Takeda Pharmaceuticals (TYO: 4502) regulatory...
Merck Forges Partnerships with BenevolentAI and Exscientia for Precision Drug Discovery
German pharmaceutical company Merck (NYSE: MRK) has announced two separate strategic collaborations with UK-based artificial...
Lynk Pharmaceuticals Secures Series C2 Financing to Advance pipeline
Lynk Pharmaceuticals Co., Ltd, a China-based pharmaceutical company, has announced the successful completion of its...
Jiangsu Hengrui Pharmaceuticals Wins NMPA Approval for Two Novel Drug Candidates
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced receiving...
Pfizer’s Litfulo Earns EU Approval as First Treatment for Severe Alopecia Areata in Teens
Pfizer (NYSE: PFE) has been granted registration authorization by the European Commission (EC) for Litfulo...
Menarini Group Secures Exclusive License for Astellas’ Smyraf in Taiwan
A. Menarini Asia-Pacific Holdings Pte. Ltd, a subsidiary of the Italy-based Menarini Group, has entered...
FDA Accepts Takeda’s Filing for Subcutaneous Entyvio as Maintenance Therapy for Crohn’s Disease
The US Food and Drug Administration (FDA) has accepted a filing from Japan-based Takeda (TYO:...
AbbVie’s Skyrizi Outperforms Janssen’s Stelara in Phase III Crohn’s Disease Trial
AbbVie (NYSE: ABBV) has announced early data from a Phase III trial that compared the...
JW Therapeutics and 2seventy Bio Expand Partnership for Cell Therapy Development
China-based cell therapy firm JW Therapeutics (HKG: 2126) and US biotech 2seventy Bio Inc., (NASDAQ:...
Sandoz Inks Deal with Samsung Bioepis for Ustekinumab Biosimilar SB17
The Sandoz (SWX: SDZ) unit of Switzerland-based Novartis (NYSE: NVS) has announced the in-licensing of...
SinoMab BioScience Receives NMPA Approval for Phase I Study of Atopic Dermatitis Drug SM17
Hong Kong-based biotechnology company SinoMab BioScience Ltd (HKG: 3681) has received approval from the National...
United Laboratories Receives Tacit Approval for JAK1 Inhibitor TUL01101 Clinical Trial
Hong Kong-listed United Laboratories International Holdings Ltd (HKG: 3933) has announced tacit clinical trial approval...
Bristol-Myers Squibb Acquires Rights to Zenas BioPharma’s Obexelimab for Autoimmune Diseases
US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a licensing and cooperation...
SinoMab BioScience’s Suciraslimab Files for Market Approval in China for Rheumatoid Arthritis
Hong Kong-based biotech company SinoMab BioScience Ltd (HKG: 3681) has announced that a market approval...
Huadong Medicine Secures Exclusive Rights to MC2 Therapeutics’ Plaque Psoriasis Therapy in China
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced a licensing agreement with Denmark-headquartered MC2...